We have demonstrated that both pharmacological and genetic approaches to reduce ERO1α activity, which is upregulated in cardiovascular disease, reduces spontaneous SR Ca2+ release and arrhythmic risk without perturbing the fine-tuned redox balance of the SR (Hamilton et al., 2022). Here, ERO1A is linked to cardiovascular disorder.